Chelsea Therapeutics International Ltd. (CHTP) is in the Pharma Industry

• Sort by

• Chelsea Therapeutics Int. Q4 2007 Earnings Call Transcript

  Chelsea Therapeutics Int. Q4 2007 Earnings Call Transcript

  Earnings calls 2008-03-11

  Tags: Call Transcript, Earnings, Seeking Alpha, Financial Accounting, Finance, Chelsea Therapeutics International Ltd.

Additional Resources

• AGT, SGN, AGIX, CHTP, SOLM, BZLFY Have Been Removed From Naked Short List Today.

  M2 PRESSWIRE-1 April 2008-BUYINS.NET: AGT, SGN, AGIX, CHTP, SOLM, BZLFY Have Been Removed From Naked Short List TodayC1994-2008 M2 COMMUNICATIONS LTD RDATE:01042008 BUYINS.NET, www.buyins.net, announced today that these select companies have been removed from the NASDAQ, AMEX and NYSE...

  Articles 2008-04-01

• NRF, WAL, CHTP, EFSC, GTOP, MCEL Have Been Added To Naked Short List Today.

  M2 PRESSWIRE-1 April 2008-BUYINS.NET: NRF, WAL, CHTP, EFSC, GTOP, MCEL Have Been Added To Naked Short List TodayC1994-2008 M2 COMMUNICATIONS LTD RDATE:01042008 BUYINS.NET, www.buyins.net, announced today that these select companies have been added to the NASDAQ, AMEX and NYSE...

  Articles 2008-04-01

• NRF, WAL, CEGE, CHTP, EFSC, GTOP Have Been Added To Naked Short List Today.

  M2 PRESSWIRE-24 March 2008-BUYINS.NET: NRF, WAL, CEGE, CHTP, EFSC, GTOP Have Been Added To Naked Short List TodayC1994-2008 M2 COMMUNICATIONS LTD RDATE:24032008 BUYINS.NET, www.buyins.net, announced today that these select companies have been added to the NASDAQ, AMEX and NYSE...

  Articles 2008-03-24

• CHELSEA THERAPEUTICS INITIATES PHASE II TRIAL OF CH-1504.(Medical condition overview)

  Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP), Charlotte, N.C., has initiated enrollment and patient dosing in a multinational, 12-week, double-blind Phase II trial designed to compare the efficacy and tolerability of CH-1504 against methotrexate MTX in rheumatoid arthritis RA patients. CH-1504,...

  Articles 2008-03-01

• Chelsea Therapeutics Initiates Ch-150 Bioequivalence Study

  Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP), Charlotte, N.C., has begun dosing volunteers in its bioequivalence study of CH-1504, an orally available metabolically inert antifolate which has demonstrated potential anti-inflammatory and anti-tumor properties. The bioequivalence study, being conducted at Swiss Pharma in Basel, Switzerland, is intended to determine a comparable...

  Articles 2007-08-01

• ATB, HOV, VG, CEGE, CHTP, CNTF Have Been Removed From Naked Short List Today.

  M2 PRESSWIRE-16 July 2007-BUYINS.NET: ATB, HOV, VG, CEGE, CHTP, CNTF Have Been Removed From Naked Short List TodayC1994-2007 M2 COMMUNICATIONS LTD RDATE:16072007 BUYINS.NET, www.buyins.net, announced today that these select companies have been removed from the NASDAQ, AMEX and NYSE naked short...

  Articles 2007-07-16

• CDZI, CHTP, CKEC, CONN, CSFL, CUTR Have Also Been Added To Naked Short List Today.

  M2 PRESSWIRE-5 July 2007-BUYINS.NET: CDZI, CHTP, CKEC, CONN, CSFL, CUTR Have Also Been Added To Naked Short List TodayC1994-2007 M2 COMMUNICATIONS LTD RDATE:05072007 BUYINS.NET, www.buyins.net, announced today that these select companies have been added to the NASDAQ, AMEX and NYSE naked...

  Articles 2007-07-05

• Teva and Active Biotech to Initiate Pivotal Phase III Trial Program of Oral Laquinimod for Relapsing Multiple Sclerosis

  JERUSALEM & LUND, Sweden -- Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Active Biotech AB (OMX NORDIC: ACTI) today announced that the companies are initiating a clinical Phase III program for laquinimod, a novel once-daily, orally administered immunomodulatory compound for the treatment of relapsing multiple sclerosis RMS....

  Articles 2007-06-07

• Laquinimod, a Novel Oral Compound, Showed Significant Reduction in Disease Activity in Patients with Relapsing-Remitting Multiple Sclerosis

  JERUSALEM, & LUND, Sweden -- Teva Pharmaceutical Industries Ltd. and Active Biotech AB today announced that data from a 36-week, randomized, double-blind, placebo-controlled Phase IIb study demonstrated that an oral 0.6 mg dose of laquinimod given daily significantly reduced magnetic resonance imaging MRI disease activity by 38...

  Articles 2007-05-01

• Chelsea Therapeutics to Raise $12.5 Million Through Equity Financing.

  M2 PRESSWIRE-19 March 2007-Catalyst Reporting: Chelsea Therapeutics to Raise $12.5 Million Through Equity FinancingC1994-2007 M2 COMMUNICATIONS LTD RDATE:19032007 Market Gainer is quickly emerging as the one stop shop for international small-cap investors looking to stay a step ahead of the ...

  Articles 2007-03-19

• Active Biotech's I-3D micro-dosing clinical trial concluded

  Active Biotech AB (Stockholm:ACTI.ST)and Chelsea TherapeuticsInternational Ltd (NASDAQ: CHTP) has performed a first humanmicro-dosing trial of an I-3D compound. The aim of the study was to determine thepharmacokineticcharacteristics of the compound in humans. The trial was performedinhealthy volunteers. The study...

  Articles 2007-03-13

• FDA GRANTS ORPHAN DRUG DESIGNATION FOR DROXIDOPA.

  Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP), Charlotte, N.C., has announced that the U.S. Food and Drug Administration FDA has granted Orphan Drug designation to its drug candidate Droxidopa for the treatment of symptomatic neurogenic orthostatic hypotension NOH in patients with Primary Autonomic Failure, a...

  Articles 2007-03-01

• Market Commentary on Chelsea Therapeutics International Ltd.

  M2 PRESSWIRE-1 February 2007-Biotech News: Market Commentary on Chelsea Therapeutics International LtdC1994-2007 M2 COMMUNICATIONS LTD RDATE:01022007 Market Commentary on Chelsea Therapeutics International Ltd (NASDAQ:CHTP) Chelsea Therapeutics International, Ltd. engages in the acquisition, development, and commercialization of pharmaceutical ...

  Articles 2007-02-01

• Droxidopa granted Orphan Drug designation.(Industry News)

  Chelsea Therapeutics International, Ltd. has announced that the FDA has granted Orphan Drug designation to its drug candidate Droxidopa for the treatment of symptomatic neurogenic orthostatic hypotension NOH in patients with Primary Autonomic Failure, a group of diseases that includes Parkinson's Disease, Pure Autonomic Failure PAF...

  Articles 2007-02-01

• Trade Alert for Chelsea Therapeutics International Ltd.

  M2 PRESSWIRE-1 February 2007-Biotech News: Trade Alert for Chelsea Therapeutics International LtdC1994-2007 M2 COMMUNICATIONS LTD RDATE:01022007 Trade Alert for Chelsea Therapeutics International Ltd (NASDAQ:CHTP) Chelsea Therapeutics International, Ltd. engages in the acquisition, development, and commercialization of pharmaceutical ...

  Articles 2007-02-01

• Global Market Perspective Review on Chelsea Therapeutics International Ltd.

  M2 PRESSWIRE-23 January 2007-www.streetinvesting.com: Global Market Perspective Review on Chelsea Therapeutics International Ltd.C1994-2007 M2 COMMUNICATIONS LTD RDATE:23012006 Please visit www.Streetinvesting.com for the full report. Although Wall Street exhibited an overall decline Monday, investors of Chelsea Therapeutics International Ltd....

  Articles 2007-01-23

• Alerts for Monday, September 11, 2006 - Featuring Conforce International, Critical Path, Manakoa Services, Chelsea Therapeutics International and More.

  M2 PRESSWIRE-11 September 2006-Stockguru.com: Alerts for Monday, September 11, 2006 - Featuring Conforce International, Critical Path, Manakoa Services, Chelsea Therapeutics International and MoreC1994-2006 M2 COMMUNICATIONS LTD RDATE:11092006 Dallas, Texas - StockGuru Pre-Market Updates for Monday include Conforce International, Inc. (OTC:...

  Articles 2006-09-11

• Price and Volume Alerts for Thursday, September 7, 2006 - Featuring PURE Bioscience , Earth Biofuels,,NanoSensors, Lifeline Biotechnologies, and More.

  M2 PRESSWIRE-7 September 2006-Stockguru.com: Price and Volume Alerts for Thursday, September 7, 2006 - Featuring PURE Bioscience , Earth Biofuels,,NanoSensors, Lifeline Biotechnologies, and MoreC1994-2006 M2 COMMUNICATIONS LTD RDATE:07092006 Dallas, Texas - StockGuru Pre-Market Updates for Thursday include PURE Bioscience (OTCBB:...

  Articles 2006-09-07

• Morning Updates for Wednesday, September 6, 2006 - Featuring: Patriot Motorcycle, Signature Leisure, NaturalNano, Inyx, and More.

  M2 PRESSWIRE-6 September 2006-Stockguru.com: Morning Updates for Wednesday, September 6, 2006 - Featuring: Patriot Motorcycle, Signature Leisure, NaturalNano, Inyx, and More.C1994-2006 M2 COMMUNICATIONS LTD RDATE:06092006 Dallas, Texas - StockGuru Pre-Market Updates for Wednesday include Patriot Motorcycle Corporation (OTC: PMCY), Signature Leisure,...

  Articles 2006-09-06